CEPP regimen
|
WikiDoc Resources for CEPP regimen |
|
Articles |
|---|
|
Most recent articles on CEPP regimen Most cited articles on CEPP regimen |
|
Media |
|
Powerpoint slides on CEPP regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on CEPP regimen at Clinical Trials.gov Clinical Trials on CEPP regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on CEPP regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on CEPP regimen Discussion groups on CEPP regimen Patient Handouts on CEPP regimen Directions to Hospitals Treating CEPP regimen Risk calculators and risk factors for CEPP regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for CEPP regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:Cyclophosphamide/Etoposide/Prednisone/Procarbazine
Overview
CEPP regimen refers to a regimen consisting of cyclophosphamide, etoposide, procarbazine and prednisone used to treat atypical presentation of Hodgkin lymphoma with severe abnormal liver function.[1]
Regimen
Ccyclophosphamide
Eetoposide
Pprocarbazine
Pprednisone
Indications
- Hodgkin lymphoma with severe abnormal liver function.[1]
References
- ↑ 1.0 1.1 Thakar K, Novero A, Das A, Lisinschi A, Mehta B, Ahmed T; et al. (2014). "CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function". Biomark Res. 2: 12. doi:10.1186/2050-7771-2-12. PMC 4078319. PMID 24991411.